Desfuroylceftiofur
Based on 1 Customer Validation
Desfuroylceftiofur is an antibacterial agent and the active metabolite of Ceftiofur sodium (HY-B0898) with an intact β-lactam ring. Desfuroylceftiofur exhibits inhibitory activity against Gram-negative and Gram-positive pathogenic bacteria of veterinary interest in vitro. Desfuroylceftiofur can be used in the research of bovine respiratory disease, porcine respiratory disease, equine lymphadenitis, bovine mastitis, turkey colibacillosis, suppurative arthritis and respiratory infections.
For research use only. We do not sell to patients.
- Purity : 85.0%
- CAS No.: 120882-22-6
- Formula: C14H15N5O5S3
- Molecular Weight:429.49
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
Desfuroylceftiofur (DXNL) (≤0.0019-4.0 μg/mL; 24 h) exhibits high in vitro activity against equine streptococcal isolates (Streptococcus equi ssp. equi, Streptococcus equi ssp. zooepidemicus) with an MIC90 of 0.03 μg/mL and against Haemophilus somnus isolates with an MIC90 of ≤0.0019 μg/mL[1].
Desfuroylceftiofur (≤0.0019-4.0 μg/mL; 24 h) exhibits high in vitro activity against Haemophilus somnus (MIC ≤0.0019 μg/mL) and equine streptococcal isolates (MIC90 = 0.03 μg/mL) in an agar dilution assay[3].
Desfuroylceftiofur (≤0.0039-4.0 μg/mL; 24 h) exhibits high in vitro activity against veterinary gram-negative bacterial isolates (MIC90 ≤2.0 μg/mL) and variable activity against gram-positive isolates, with highest potency against streptococci (MIC90 ≤0.5 μg/mL) and lowest potency against staphylococci (MIC90 = 4.0-8.0 μg/mL) in a microdilution assay[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Horses (3.2 years; 436.5 kg)[2]
-
Dosage:2 g per animal (regional intravenous perfusion); 2 g per animal (systemic intravenous injection)
-
Administration:regional intravenous perfusion (infused over 90-120 seconds); systemic intravenous injection (jugular vein)
-
Result:Reached a peak mean synovial fluid concentration of 397.7 μg/mL and remained above 1 μg/mL (MIC90) for more than 24 hours after regional intravenous perfusion.
Reached a peak mean synovial fluid concentration of 2.72 μg/mL and fell below 1 μg/mL between 8 and 12 hours post-injection after systemic intravenous injection.
Showed significantly lower plasma concentrations during tourniquet inflation period after regional perfusion compared to systemic injection; after tourniquet deflation, plasma concentrations followed a similar elimination pattern between the two routes.
Chemical Information
-
CAS No. 120882-22-6
-
Appearance Solid
-
Molecular Weight 429.49
-
Formula C14H15N5O5S3
-
Color Off-white to light yellow
-
SMILES
O=C(C(N12)=C(CS)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
Ethanol : 10 mg/mL (23.28 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.3283 mL | 11.6417 mL | 23.2834 mL | 58.2086 mL |
| 5 mM | 0.4657 mL | 2.3283 mL | 4.6567 mL | 11.6417 mL | |
| 10 mM | 0.2328 mL | 1.1642 mL | 2.3283 mL | 5.8209 mL | |
| 15 mM | 0.1552 mL | 0.7761 mL | 1.5522 mL | 3.8806 mL | |
| 20 mM | 0.1164 mL | 0.5821 mL | 1.1642 mL | 2.9104 mL |
Keywords
- Desfuroylceftiofur
- 120882-22-6
- Bacterial
- Drug Metabolite
- Streptococcus equi ssp. zooepidemicus
- equine lymphadenitis
- gram-positive bacterial pathogens
- bovine mastitis
- swine respiratory disease
- gram-negative bacterial pathogens
- Streptococcus equi ssp. equi
- turkey colibacillosis
- Haemophilus somnus
- bovine respiratory disease
- Inhibitor
- inhibitor
- inhibit